2’,5’-dihydroxyflavone | 92439-19-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 2’,5’-dihydroxyflavone
• 英文别名: 2′,5′-dihydroxyflavone；2-(2,5-dihydroxy-phenyl)-chromen-4-one；2-(2,5-Dihydroxy-phenyl)-chromen-4-on；2',5'-Dihydroxyflavone；2-(2,5-dihydroxyphenyl)chromen-4-one
• CAS: 92439-19-5
• 化学式: C₁₅H₁₀O₄
• 分子量: 254.242
• InChiKey: QOULGRDJCDSRNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2’,5’-dihydroxyflavone 、 乙酸酐 在 sodium acetate 作用下， 生成 2-(2,5-diacetoxy-phenyl)-chromen-4-one
  参考文献：
  名称：

  Gallagher et al., Journal of the Chemical Society, 1953, p. 3770,3777

  摘要：

  DOI：
• 作为产物：
  描述：

  2,5-二甲氧基黄酮 在 三氯化铝 、 苯 作用下， 生成 2’,5’-dihydroxyflavone
  参考文献：
  名称：

  Gallagher et al., Journal of the Chemical Society, 1953, p. 3770,3777

  摘要：

  DOI：

文献信息

• IMMUNITY ENHANCING ADJUVANT THAT CAN BE ADMINISTERED IN COMBINATION WITH OIL EMULSION, AND VACCINE COMPOSITION FOR FOOT-AND-MOUTH DISEASE COMPRISING SAME
  申请人：REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY)

  公开号：EP3939608A1

  公开（公告）日：2022-01-19

  The present invention relates to an adjuvant composition for a foot-and-mouth disease vaccine. The present invention can provide induction of a strong immune response through simultaneous induction of cellular and humoral immunity in cloven-hoofed animals such as cattle, pigs, etc., for prevention and treatment of a foot-and-mouth disease outbreak, a safe and optimized adjuvant composition, and a vaccine composition comprising same. In addition, when the foot-and-mouth disease breaks out, the present invention can be used to effectively cope with the outbreak as an emergency vaccine in the field, and can provide a stabilized systematic vaccine to cloven-hoofed animals.

  本发明涉及一种用于口蹄疫疫苗的佐剂组合物。本发明可以通过同时诱导牛、猪等蹄类动物的细胞免疫和体液免疫来诱导其产生强烈的免疫应答，从而预防和治疗口蹄疫的爆发，本发明还提供了一种安全、优化的佐剂组合物，以及包含该佐剂组合物的疫苗组合物。此外，当口蹄疫爆发时，本发明可作为应急疫苗在野外有效应对疫情，并可为蹄类动物提供稳定的系统疫苗。
• Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
  申请人：Innate Tumor Immunity, Inc.

  公开号：US10723756B2

  公开（公告）日：2020-07-28

  This disclosure features chemical entities (e.g., a compound that modulates (e.g., agonizes) Stimulator of Interferon Genes (STING), or a pharmaceutically acceptable salt, and/or hydrate, and/or coccrystal, and/or drug combination of the compound) that are useful, e.g., for treating a condition, disease or disorder in which a decrease or increase in STING activity (e.g., a decrease, e.g., a condition, disease or disorder associated with repressed or impaired STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，调节（如激动）干扰素基因刺激器（STING）的化合物，或该化合物的药学上可接受的盐、和/或水合物、和/或球晶、和/或药物组合）可用于，例如、用于治疗 STING 活性降低或增加（例如，STING 信号转导受抑制或受损相关的状况、疾病或紊乱）导致受试者（例如人类）的病理和/或症状和/或状况、疾病或紊乱（例如癌症）进展的状况、疾病或紊乱。本公开的内容还包括组合物以及使用和制造组合物的其它方法。
• Compounds and compositions for treating conditions associated with sting activity
  申请人：Innate Tumor Immunity, Inc.

  公开号：US11505571B2

  公开（公告）日：2022-11-22

  This disclosure features chemical entities (e.g., a compound that modulates (e.g., agonizes) Stimulator of Interferon Genes (STING), or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that are useful, e.g., for treating a condition, disease or disorder in which a decrease or increase in STING activity (e.g., a decrease, e.g., a condition, disease or disorder associated with repressed or impaired STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，调节（例如，激动）干扰素基因刺激器（STING）的化合物，或该化合物的药学上可接受的盐、和/或水合物、和/或共晶体、和/或药物组合）有助于，例如、用于治疗 STING 活性降低或增加（例如，STING 信号转导受抑制或受损相关的状况、疾病或紊乱）导致受试者（例如人类）的病理和/或症状和/或状况、疾病或紊乱（例如癌症）进展的状况、疾病或紊乱。本公开的内容还包括组合物以及使用和制造组合物的其它方法。
• USE OF STING AGONISTS TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION
  申请人：Drexel University

  公开号：EP3060056A2

  公开（公告）日：2016-08-31
• COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE
  申请人：The Regents Of The University Of Michigan

  公开号：EP3820534A1

  公开（公告）日：2021-05-19